

AD\_\_\_\_\_

Award Number: W81XWH-06-1-0653

TITLE: Forkhead Box Protein 1 (Foxa1) and the Sumoylation Pathway that Regulates Foxa1 Stability are Potential Targets for Breast Cancer Treatment

PRINCIPAL INVESTIGATOR: Narasimhaswamy S. Belaguli. D.V.M., Ph.D.

CONTRACTING ORGANIZATION: Baylor College of Medicine  
Houston, TX 77030

REPORT DATE: September 2007

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. <b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</b>					
1. REPORT DATE (DD-MM-YYYY) 01-09-2007		2. REPORT TYPE Final		3. DATES COVERED (From - To) 7 AUG 2006 - 6 AUG 2007	
4. TITLE AND SUBTITLE  Forkhead Box Protein 1 (Foxa1) and the Sumoylation Pathway that Regulates Foxa1 Stability are Potential Targets for Breast Cancer Treatment				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-06-1-0653	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Narasimhaswamy S. Belaguli. D.V.M., Ph.D.  E-Mail: elaguli@bcm.tmc.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)  Baylor College of Medicine Houston, TX 77030				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Purpose: The purpose of this study is to determine the mechanisms by which the posttranslational SUMO modification regulates the activity of the forkhead box protein A1 (Foxa1). Major findings: We have demonstrated the sumoylation of Foxa1 in several breast cancer cell lines. Analysis of the Foxa1 protein sequence identified two potential sumoylation sites. Lysine to arginine substitution of the conserved lysine (K6) abolished Foxa1 sumoylation suggesting that the K6 is the primary sumoylation site. In contrast to the related forkhead box protein A2 (Foxa2) in which the K6R mutation induced protein destabilization, mutation of the conserved K6 sumoylation site did not strongly affect the stability of the Foxa1 protein. In transfection experiments, Foxa1 induced activation of the p27Kip1 promoter activity was downregulated by SUMO-1 demonstrating that SUMO-1 negatively regulates Foxa1 activity. On the contrary, the nonsumoylatable mutant of Foxa1 (Foxa1K6R) activated the p27Kip1 promoter to a lower extent compared with the wild type Foxa1 suggesting that the K6 and its modification/s are required for the transcriptional activity of Foxa1. Together, our results show that Foxa1 is modified by sumoylation on lysine, K6, and the SUMO modification of Foxa1 modulates the activity of Foxa1 on its target genes in breast cancer cells.					
15. SUBJECT TERMS Estrogens, Estrogen receptor, Foxa1, SUMO-1, Ubc9, PIAS1, Sumoylation					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	9	19b. TELEPHONE NUMBER (include area code)

## Table of Contents


	<u>Page</u>
Introduction.....	1
Body.....	1-5
Key Research Accomplishments.....	5
Reportable Outcomes.....	5
Conclusion.....	5
References.....	5-6
Appendices.....	6

## Introduction:

Estradiol (E2) and its receptor, estrogen receptor (ER) alpha, regulate the growth potential of breast cancer cells. Recent genome wide chromatin immunoprecipitation (ChIP) and bioinformatics studies have shown that the specificity of ER target genes is determined by the forkhead box transcription factor A1 (Foxa1), which binds in close proximity to ER binding sites (1,2,5,6). Foxa1 was required for binding of ER, regulation of ER target genes and estrogen-induced reentry of breast cancer cells into cell cycle (2,5). Recently, the breast cancer susceptibility gene, BRCA1, was shown to stabilize Foxa1 suggesting that Foxa1 protein is regulated posttranslationally through stabilization and destabilization mechanisms (8). In the course of our studies on pancreatic islet gene regulation by the related forkhead box protein A2 (Foxa2), we have found that Foxa2 is sumoylated on lysine K6. Abolishing sumoylation by targeted mutagenesis of the Sumo acceptor lysine or by overexpression of the dominant negative sumo-conjugating enzyme, Ubc9, resulted in destabilization and loss of Foxa2 protein expression. In nude mice tumorigenicity assays, Ubc9, which is upregulated in ovarian cancers, promoted, while dominant negative Ubc9 interfered with the growth of MCF7 breast cancer cells (7). Foxa1 is highly similar to Foxa2 and the sumoylation sites are conserved. Based on these observations we have hypothesized that Foxa1 is sumoylated and the SUMO modification of Foxa1 plays an important role in determining the tumorigenic potential of breast cancer cells.

## Body:


**Task 1.** As proposed under the objective 1 of our grant proposal, we have examined whether Foxa1 is sumoylated in breast cancer cells by immunoprecipitation (IP) and western blotting analysis. Equal amounts of cell lysates prepared from ER positive, Foxa1 expressing MCF7 breast cancer cells were IPd with SUMO-1, SUMO-2/3 antibodies coupled to agarose beads. Since SUMO-2 and SUMO-3 antibodies cross-react with each other due to strong sequence homology (98% aminoacid identity between mature SUMO-2 and SUMO-3) (3), antibodies that react with both SUMO-2 and SUMO-3 were used for IPs. IP reactions with normal mouse antibody coupled agarose beads served as a negative control. The IPs were resolved and analyzed by western blotting with Foxa1 antibodies. As shown in figure 1, IP with SUMO-1 antibodies resulted in a doublet of Foxa1 bands (lane 1, indicated by arrows). The lower band of the doublets was the predominant band in SUMO-2/3 IPs (figure 1, lane 2). Further, an additional band (indicated by arrowhead) and a slow migrating smear (indicated by bracket) were apparent in SUMO-2/3 antibody IPs. Currently, we do not know the identity of the additional Foxa1 antibody reactive band and the smear in SUMO-2/3 IPs. The additional band could represent Foxa1 sumoylated at multiple sites by SUMO-2/3. The high molecular weight smear in SUMO-2/3 IP could have resulted from the unique ability of SUMO-2/3 but not SUMO-1 to undergo poly-sumoylation as has been suggested earlier for other SUMO-2/3 substrates (3). The results of these experiments show that the endogenous Foxa1 expressed in MCF7 breast cancer cells undergoes sumoylation by SUMO-1 and SUMO-2/3. We did not examine the sumoylation status of Foxa1 in MDA-MB-231 cells as these cells do not express endogenous Foxa1 (9).



**Figure 1. Foxa1 is sumoylated in MCF7 breast cancer cells.** One mg of MCF7 cell lysates were immunoprecipitated using 4 µg of SUMO-1 (lane 1), SUMO-2/3 (lane 2) and normal mouse antibody (lane 3) coupled agarose beads. The IPs were extensively washed, resolved on 8% polyacrylamide-SDS gel and analyzed by western blotting with Foxa1 antibody. Sumoylated Foxa1 doublets are shown by arrows. Additional Foxa1 antibody reactive band and a high molecular weight smear are indicated by an arrowhead and a bracket.


To determine if Foxa1 is preferentially modified by a particular SUMO, we transfected MCF7 cells with expression vectors expressing HA epitope tagged Foxa1 along with or without FLAG epitope tagged SUMO-1, SUMO-2 or SUMO-3. Forty eight hours following transfection, cells were lysed and analyzed by IP with mouse HA antibody followed by western blotting with rabbit HA antibody. As shown in figure 2 (upper panels in lanes 2,3,5,6,8,9) IPd Foxa1 resolved as a doublet (indicated by arrow). Cotransfection of SUMO-1, -2 or -3 expression vectors resulted in the appearance of slow migrating sumoylated Foxa1 (figure 2, upper panels, lanes 3,6,9, indicated by arrowhead). The sumoylated bands lighted up specifically when the blots were stripped and reprobed with the FLAG antibody, which recognizes the FLAG epitope on transfected SUMO-1, -2 and -3 confirming that these slow migrating bands correspond to sumoylated Foxa1 (indicated by asterisk in figure 2, lower panels, lanes 3,6,9). Foxa1 was strongly sumoylated by SUMO-1 compared to SUMO-2 and SUMO-3 (figure 2, upper panels, lanes 3,6,9). Further, SUMO-1 sumoylated Foxa1 migrated as a doublet while SUMO-2 and SUMO-3 sumoylated Foxa1 migrated as single bands. Together, these results show that while Foxa1 is sumoylated by all three SUMOs, Foxa1 is a preferred substrate for sumoylation by SUMO-1.

We have also examined whether Foxa1 is sumoylated in ER negative MDA-MB-231 cells by transfecting these cells with expression vectors expressing HA epitope tagged Foxa1 with or without FLAG epitope tagged SUMO-1, SUMO-2 or SUMO-3. Forty eight hours following transfection, cells were lysed and analyzed by IP with mouse HA antibody followed by western blotting with rabbit HA antibody. As seen in MCF7 cells, transfected Foxa1 resolved as a doublet in MDA-MB-231 cells. Transfected Foxa1 was sumoylated in these cells by SUMO-1, SUMO-2 and SUMO-3 (figure 3, upper panels, lanes 3,6,9). Similar to MCF7 cells, Foxa1 was preferentially sumoylated by SUMO-1 in MDA-MB-231 cells (figure 3, upper panels, compare lanes 3,6,9). Our results suggest that although MDA-MB-231 cells do not express endogenous Foxa1, they do sumoylate the transfected Foxa1 in essentially similar manner to that of the Foxa1 positive MCF7 cells.



**Figure 2. Foxa1 is sumoylated in MCF7 breast cancer cells.**

Subconfluent MCF7 cells were transfected with 1 µg of expression vectors for HA epitope tagged Foxa1 (lanes 2,3,5,6,8,9) with FLAG epitope tagged SUMO-1 (lane 3), FLAG epitope tagged SUMO-2 (lane 6) and FLAG epitope tagged SUMO-3 (lane 9). Cells corresponding to lanes 1, 4, and 7 were transfected with FLAG epitope tagged SUMO-1, SUMO-2 and SUMO-3, respectively. Total amount of transfected DNA was adjusted to 2 µg using pCDNA3 empty vector. Forty eight hours following transfection, equal amounts of cell lysates were IPd with mouse HA antibody and analyzed by western blotting with rabbit HA antibody (upper panels). Unsumoylated Foxa1 is indicated by an arrow and the sumoylated Foxa1 by arrow head in the upper panel. The blots were stripped and reprobed with rabbit FLAG antibody and shown in lower panels. Asterisks in the lower panel indicates the bands that correspond to the sumoylated Foxa1 bands shown in the upper panels. Additional sumoylated bands are shown by a bracket in the lower panel.





**Figure 3. Foxa1 is sumoylated in MDA-MB-231 breast cancer cells.**

Subconfluent MDA-MB-231 cells were transfected with 1 µg of expression vectors for HA epitope tagged Foxa1 (lanes 2,3,5,6,8,9) with FLAG epitope tagged SUMO-1 (lane 3), FLAG epitope tagged SUMO-2 (lane 6) and FLAG epitope tagged SUMO-3 (lane 9). Cells corresponding to lanes 1, 4, and 7 were transfected with FLAG epitope tagged SUMO-1, SUMO-2 and SUMO-3, respectively. Total amount of transfected DNA was adjusted to 2 µg using pCDNA3 empty vector. Forty eight hours following transfection, equal amounts of cell lysates were IPd with mouse HA antibody and analyzed by western blotting with rabbit HA antibody (upper panels). Unsumoylated Foxa1 is indicated by an arrow and the sumoylated Foxa1 by arrow head in the upper panel. The blots were stripped and reprobed with rabbit FLAG antibody and shown in lower panels. Black asterisks in the lower panel indicates the bands that correspond to the sumoylated Foxa1 bands shown in the upper panels. Additional sumoylated bands are shown by a bracket in the lower panel. Signals from the incompletely stripped Foxa1 band is shown by white asterisks in the lower panels.

**Task 2.** As proposed under the objective 2 of our grant proposal, we have generated MCF7 cells stably expressing the FLAG epitope tagged wild-type or dominant negative Ubc9 (DN Ubc9). Ubc9 is an E2-conjugating enzyme essential for sumoylation of SUMO substrates and DN Ubc9 has been shown to downregulate sumoylation of SUMO substrates (4). By using Quick Change mutagenesis system (Stratagene Inc, La Jolla, CA), we have generated a DN Ubc9 by mutating the conserved cysteine 93 to serine. Wild type Ubc9 and DN Ubc9 were cloned into G418 selectable, FLAG epitope containing pCMVTag vectors. MCF7 cells transfected with Ubc9, DN Ubc9 or the pCMVTagC empty vector were selected for growth in G418 containing medium (1 mg/ml). To minimize the variation among cell lines, G418 resistant colonies were pooled and the


expression of Ubc9 and DN Ubc9 in these pools were confirmed by western blotting analysis (figure 4, top panel). Wild type Ubc9 expression was lower in these pools compared with the DN Ubc9. To determine whether the steady state levels of Foxa1 is altered by expression of DN Ubc9, we analyzed equal amounts of cell lysates from Ubc9, DN Ubc9 and vector transfected control cells by western blotting with Foxa1 antibody. Contrary to our expectation, Foxa1 levels (normalized to actin internal standard) were not downregulated by DN Ubc9 expression (figure 4, bottom panel). We further examined if the stability of Foxa1 protein is altered in these stable pools by performing cycloheximide (CHX) chase experiments.

Pooled clones were treated with CHX (50  $\mu$ g/ml final concentration) and harvested at 0, 1, 2, 4, 6 and 8-hour time points and analyzed by western blotting with the Foxa1 antibody or the internal standard actin antibody. A representative experiment is shown in the figure 5. Foxa1 and the corresponding actin signals for each time point were quantitated by densitometry. Normalized Foxa1 signals from 3 experiments were used to calculate



the half-life of Foxa1 protein. Half-life of Foxa1 protein was approximately 3 hours 45 minutes in Tag2C, Ubc9 and DN Ubc9 expressing cells. Together, these experiments indicate that modulating the activity of SUMO ubiquitin conjugating enzyme does not affect Foxa1 stability.

We have also used an alternate approach to examine whether sumoylation affects the stability of Foxa1 protein. Foxa1 contains 2 potential sumoylation sites: lysine 6 and lysine 265 (figure 6, panel A). We mutated the conserved lysine (K) 6 into arginine (R). HA epitope tagged Foxa1 (figure 6, lanes 1,2) or Foxa1K6R (figure 6, lanes 3,4) were transfected with out (lanes 1,3) or with (lanes 2,4) FLAG epitope tagged SUMO-1 into MCF7 cells (figure 6B, top panel) and MDA-MB-231 cells (figure 6B, bottom panel). Equal amounts of cell lysates were IPd with mouse HA antibody and analyzed by western blotting with rabbit HA antibody. As shown in figure 6B. K6R mutation abolished sumoylation of Foxa1 in both MCF7 cells (top panel, figure 6B) and MDA-MB-231 cells (bottom panel, figure 6B). Despite loss if sumoylation, steady state levels of Foxa1 was not altered in both MCF7 and MDA-MB-231 cells suggesting that Foxa1 protein expression levels are not affected by the sumoylation.



**Task 3.** As proposed under the **objective 3**, we attempted to strongly and stably express Foxa1 in MCF7 cells. Although Foxa1 can be expressed transiently in MCF7 and MDA-MB-231 cells, stable expression from CMV promoter resulted in loss of clonal expansion of cells and eventual loss of cell lines. Therefore stable MCF7 cell lines expressing tetracycline inducible Foxa1 are being developed. Based on a previously published work showing activation of p27<sup>Kip1</sup> promoter by Foxa1 (8), we reasoned that strong activation of the endogenous p27<sup>Kip1</sup> cell cycle inhibitor may be responsible at least in part for our inability to derive stable MCF7 cell lines expressing constitutively high levels of Foxa1. Therefore we examined the effect of wild type and sumoylation deficient mutant of Foxa1 and SUMO-1 on the activity of p27<sup>Kip1</sup> promoter. Foxa1 induced activation of the p27<sup>Kip1</sup> promoter activity was downregulated by SUMO-1 demonstrating that SUMO-1 negatively regulates Foxa1 activity. On the contrary, the nonsumoylatable mutant of Foxa1 (Foxa1K6R) activated the p27<sup>Kip1</sup> promoter to a lower extent compared with the wild type Foxa1 suggesting that the K6 and its modification/s are required for the transcriptional activity of Foxa1 (figure 7).

The animal experiments proposed under **task 3** will be performed once conditional Foxa1 overexpressing MCF7 cell lines are derived.

**Task 4.** Due to our inability to obtain Foxa1 overexpressing MCF7 cells, we have not been able to accomplish this task

#### Key research accomplishments:


1. Demonstration of sumoylation of endogenous Foxa1 in MCF7.
2. Demonstrating that transfected Foxa1 is sumoylated by SUMO-1, SUMO-2 and SUMO-3 in both MCF7 and MDA-MB-231 cells.
3. Demonstration of preferential sumoylation of Foxa1 by SUMO-1 in MCF7 and MDA-MB-231 breast cancer cells.
4. Mapping the sumoylation sites and determining that sumoylation does not affect the stability of Foxa1 in MCF7 and MDA-MB-231 cells.
5. Demonstrating that strong stable expression of Foxa1 affects clonal expansion and causes loss of cell lines.
6. Demonstrating that sumoylation modulates the Foxa1 mediated activation of its target genes such as p27<sup>Kip1</sup>.

#### Reportable outcomes:

This work is being submitted for presentation at the upcoming Era of Hope meeting. This work will be submitted for publication in a reputed journal that publishes cancer related work once the work is completed.

#### Conclusions:

Together, our results show that Foxa1 is modified by sumoylation on lysine, K6, and the SUMO modification of Foxa1 modulates the activity of Foxa1 on its target gene promoters such as, p27<sup>Kip1</sup>. Further, our work suggests that the K6 residue of Foxa1 may be a target for multiple competing modifications and the nature of the modification/s determines the activity of Foxa1 towards its target genes.



#### Reference List

1. **Carroll, J. S. and M. Brown.** 2006. Estrogen receptor target gene: an evolving concept. *Mol. Endocrinol.* **20**:1707-1714.



2. **Carroll, J. S., X. S. Liu, A. S. Brodsky, W. Li, C. A. Meyer, A. J. Szary, J. Eeckhoute, W. Shao, E. V. Hestermann, T. R. Geistlinger, E. A. Fox, P. A. Silver, and M. Brown.** 2005. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. *Cell* **122**:33-43.
3. **Geiss-Friedlander, R. and F. Melchior.** 2007. Concepts in sumoylation: a decade on. *Nat. Rev. Mol. Cell Biol.* **8**:947-956.
4. **Giorgino, F., R. O. de, L. Laviola, C. Montrone, S. Perrini, K. C. McCowen, and R. J. Smith.** 2000. The sentrin-conjugating enzyme mUbc9 interacts with GLUT4 and GLUT1 glucose transporters and regulates transporter levels in skeletal muscle cells. *Proc. Natl. Acad. Sci. U. S. A* **97**:1125-1130.
5. **Laganiere, J., G. Deblois, C. Lefebvre, A. R. Bataille, F. Robert, and V. Giguere.** 2005. From the Cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. *Proc. Natl. Acad. Sci. U. S. A* **102**:11651-11656.
6. **Laganiere, J. and V. Giguere.** 2006. [Decoding the mode of action of the estrogen receptor through functional genomics]. *Bull. Cancer* **93**:883-887.
7. **Mo, Y. Y., Y. Yu, E. Theodosiou, P. L. Rachel Ee, and W. T. Beck.** 2005. A role for Ubc9 in tumorigenesis. *Oncogene* **24**:2677-2683.
8. **Williamson, E. A., I. Wolf, J. O'Kelly, S. Bose, S. Tanosaki, and H. P. Koeffler.** 2006. BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase inhibitor p27(Kip1). *Oncogene* **25**:1391-1399.
9. **Yamaguchi, N., E. Ito, S. Azuma, R. Honma, Y. Yanagisawa, A. Nishikawa, M. Kawamura, J. Imai, K. Tatsuta, J. Inoue, K. Semba, and S. Watanabe.** 2008. FoxA1 as a lineage-specific oncogene in luminal type breast cancer. *Biochem. Biophys. Res. Commun.* **365**:711-717.

**Appendices:** None